Today: 20 March 2026
Subscribe
Browse Category

Healthcare Innovation 8 October 2025 - 9 October 2025

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics shares surged to around $23 midday Oct. 9 after opening at $24.50, following a prior close of $7. Market cap jumped to over $500 million from under $100 million. The stock debuted on Nasdaq Oct. 8 via direct listing and has traded with extreme volatility, more than tripling in value amid speculative interest. No new FDA approvals were announced this week.
9 October 2025
··
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Tempus AI shares closed at a record $102.31 on October 8, 2025, nearly tripling year-to-date after FDA clearance for new AI diagnostics and the $81.3 million acquisition of Paige. Q2 revenue surged 89.6% to $314.6 million, with net losses narrowing and positive adjusted EBITDA forecast for 2025. Market cap stands near $17 billion.
8 October 2025
···
1 2

Stock Market Today

  • Centene Launches Community Programs Amid Depressed Stock Price: What Investors Should Know
    March 20, 2026, 6:30 AM EDT. Centene Corp subsidiaries have initiated community-focused programs targeting behavioral health, job training, housing support, and diabetes care, aiming to assist underserved populations across major U.S. markets. These efforts come as Centene shares (NYSE:CNC) remain under pressure, with a recent price of $35.57, down 13.7% in the past month and 40.3% over one year. Investors should monitor these initiatives closely for insights into Centene's regulatory relations and potential impact on medical loss ratios and membership retention. Despite current headwinds, the stock trades nearly 17% below analyst targets and is marked as undervalued by Simply Wall St. Key risks include rising costs without clear reimbursement or measurable health outcomes.
Go toTop